We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTXW
151
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$45K ﹤0.01%
1,237,952
-24,500
-2% -$2.37K
FCEL icon
152
PUT
FuelCell Energy
FCEL
$1.62B
$42K ﹤0.01%
+1
New +$540
OREX
153
DELISTED
Orexigen Therapeutics, Inc.
OREX
$42K ﹤0.01%
19,700
– –
OREX
154
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$42K ﹤0.01%
197
– –
NSPRW
155
DELISTED
InspireMD, Inc. Warrants
NSPRW
$41K ﹤0.01%
1,194,322
-15,103
-1% -$1.26K
NSPRZ
156
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$40K ﹤0.01%
2,002,648
+300
+0% +$26
BNTCW
157
DELISTED
Benitec Biopharma Limited
BNTCW
$27K ﹤0.01%
90,193
– –
SPHS
158
PUT
DELISTED
Sophiris Bio, Inc.
SPHS
$24K ﹤0.01%
+112
New +$232
FCEL icon
159
FuelCell Energy
FCEL
$1.62B
$21K ﹤0.01%
+33
New +$17.8K
OASM
160
DELISTED
Oasmia Pharmaceutical AB
OASM
$20K ﹤0.01%
19,000
– –
ONSIW
161
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$18K ﹤0.01%
158,295
-179,818
-53% -$23K
ONSIZ
162
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$13K ﹤0.01%
260,018
-240,606
-48% -$15.8K
IMUC.WS
163
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$8K ﹤0.01%
420,103
+5,000
+1% +$240
CYTR
164
PUT
DELISTED
CytRx Corp
CYTR
$4K ﹤0.01%
17
-26
-60% -$88
ABUS icon
165
CALL
Arbutus Biopharma
ABUS
$875M
– –
-1,311
Closed -$472K
ABUS icon
166
Arbutus Biopharma
ABUS
$875M
– –
-248,600
Closed -$895K
ADVM
167
DELISTED
Adverum Biotechnologies
ADVM
– –
-11,000
Closed -$275K
ALDX icon
168
Aldeyra Therapeutics
ALDX
$95.9M
– –
-97,704
Closed -$454K
BNBX
169
DELISTED
BNB PLUS CORP
BNBX
– –
-2
Closed -$1.74M
ATEC icon
170
Alphatec Holdings
ATEC
$1.43B
– –
-334,622
Closed -$629K
ATOS icon
171
Atossa Therapeutics
ATOS
$23.7M
– –
-1,617
Closed -$150K
BCLI
172
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-1,115
Closed -$70K
BLRX
173
BioLineRX
BLRX
$12.3M
– –
-4,915
Closed -$2.51M
CAPR icon
174
Capricor Therapeutics
CAPR
$380M
– –
-2,420
Closed -$20K
CRIS icon
175
CALL
Curis
CRIS
$9.78M
– –
0
– -$32K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.